Rolf Stahel, chief executive of Shire Pharmaceuticals, is 'aggressively' seeking deals. The market thought it had identified the target in Irish group Elan, vulnerable after a profits warning and accounting controversies that have decimated its price. Shire, helped by an upgrade from UBS Warburg, gained 5p at 761p, while Elan, which specialises in dermatology products, bounced 102p to 1097 1/2p.